Search

Search Constraints

You searched for: Author/Creator Alexander, Roberta Vezza

Search Results

1. 237 Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus. (April 2019)

2. 501 Role of platelet-bound complement activation product (PC4d) in predicting risk of future thrombotic events in systemic lupus erythematosus. (14th December 2022)

3. 616 Lower hydroxychloroquine blood levels are associated with higher Type 1 and 2 lupus activities. (14th December 2022)

4. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. Issue 1 (12th July 2021)

5. A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus. Issue 2 (4th February 2021)

7. Cell-bound complement activation products associate with lupus severity in SLE. Issue 1 (5th May 2020)

8. Cell-bound complement activation products associate with lupus severity in SLE. Issue 1 (5th May 2020)

9. Cell-bound complement activation products associate with lupus severity in SLE. Issue 1 (5th May 2020)

10. Cell-bound complement activation products associate with lupus severity in SLE. Issue 1 (5th May 2020)